Dianthus Therapeutics Inc (DNTH)
26.00
-0.96
(-3.56%)
USD |
NASDAQ |
Jun 14, 16:00
25.94
-0.06
(-0.21%)
After-Hours: 20:00
Dianthus Therapeutics EPS Diluted (Quarterly): -0.54 for March 31, 2024
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.54 |
| December 31, 2023 | -0.7129 |
| September 30, 2023 | -3.78 |
| Date | Value |
|---|---|
| March 31, 2023 | -0.4784 |
| December 31, 2022 | -0.6827 |
| September 30, 2022 | -0.5253 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-3.78
Minimum
Sep 2023
-0.4784
Maximum
Mar 2023
-1.120
Average
-0.6113
Median
EPS Diluted (Quarterly) Benchmarks
| CEL-SCI Corp | -0.14 |
| AIM ImmunoTech Inc | -0.12 |
| IGC Pharma Inc | -0.09 |
| NovaBay Pharmaceuticals Inc | -5.25 |
| Protalix BioTherapeutics Inc | -0.06 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -13.75M |
| Revenue (Quarterly) | 0.874M |
| Total Expenses (Quarterly) | 18.72M |
| Enterprise Value | 386.05M |
| Profit Margin (Quarterly) | -1.57K% |
| Earnings Yield | -21.20% |
| Normalized Earnings Yield | -21.17 |